Company’s 36-month beta value is 0.48.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLRX is 2.11M, and currently, short sellers hold a 1.49% ratio of that floaft. The average trading volume of SLRX on July 09, 2025 was 1.21M shares.
SLRX) stock’s latest price update
The stock price of Salarius Pharmaceuticals Inc (NASDAQ: SLRX) has jumped by 3.68% compared to previous close of $0.79. Despite this, the company has seen a fall of -6.63% in its stock price over the last five trading days. globenewswire.com reported 2025-07-09 that Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year Company continues to advance its contemplated merger with Decoy Therapeutics HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that two animal studies recently published in peer-reviewed journals provide additional insight into the role of inhibiting lysine-demethylase 1 (LSD1 or KDM1A), a well-validated target in hematologic and solid tumors. Salarius’ seclidemstat (SP-2577) is a first-in-class, orally bioavailable LSD1 inhibitor that is being evaluated in an investigator-initiated Phase 1/2 clinical study at MD Anderson Cancer Center (MDACC) as a potential treatment for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) in patients with limited treatment options.
SLRX’s Market Performance
Salarius Pharmaceuticals Inc (SLRX) has experienced a -6.63% fall in stock performance for the past week, with a 13.36% rise in the past month, and a 13.81% rise in the past quarter. The volatility ratio for the week is 8.27%, and the volatility levels for the past 30 days are at 13.61% for SLRX.. The simple moving average for the past 20 days is -9.15% for SLRX’s stock, with a -37.11% simple moving average for the past 200 days.
Analysts’ Opinion of SLRX
Many brokerage firms have already submitted their reports for SLRX stocks, with Ladenburg Thalmann repeating the rating for SLRX by listing it as a “Buy.” The predicted price for SLRX in the upcoming period, according to Ladenburg Thalmann is $3.80 based on the research report published on April 27, 2020 of the previous year 2020.
SLRX Trading at -0.19% from the 50-Day Moving Average
After a stumble in the market that brought SLRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.62% of loss for the given period.
Stock Fundamentals for SLRX
The total capital return value is set at -7.5. Equity return is now at value -300.16, with -154.23 for asset returns.
Based on Salarius Pharmaceuticals Inc (SLRX), the company’s capital structure generated 0.64 points at debt to capital in total, while cash flow to debt ratio is standing at -38.79.
Currently, EBITDA for the company is -5.57 million with net debt to EBITDA at 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.89.
Conclusion
In a nutshell, Salarius Pharmaceuticals Inc (SLRX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
